{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:36:35Z","timestamp":1782286595135,"version":"3.54.5"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Oral Oncology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.oraloncology.2024.106971","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T19:26:29Z","timestamp":1722021989000},"page":"106971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Profound ctDNA and radiological responses after 2 cycles of avelumab in a metastatic Merkel cell carcinoma of the head and neck"],"prefix":"10.1016","volume":"157","author":[{"given":"Santiago","family":"Cabezas-Camarero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"P\u00e9rez-Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Riquelme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Rom\u00e1n-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.oraloncology.2024.106971_b0005","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.oraloncology.2024.106971_b0010","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamadermatol.2021.6096","article-title":"Recurrence and mortality risk of Merkel cell carcinoma by cancer stage and time from diagnosis","volume":"158","author":"McEvoy","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.oraloncology.2024.106971_b0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.det.2022.07.015","article-title":"Merkel cell carcinoma","volume":"41","author":"Lewis","year":"2023","journal-title":"Dermatol Clin"},{"issue":"5","key":"10.1016\/j.oraloncology.2024.106971_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103461","article-title":"First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study","volume":"9","author":"D\u2019Angelo","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.oraloncology.2024.106971_b0025","doi-asserted-by":"crossref","first-page":"e000674","DOI":"10.1136\/jitc-2020-000674","article-title":"Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial","volume":"8","author":"D\u2019Angelo","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.oraloncology.2024.106971_b0030","doi-asserted-by":"crossref","first-page":"e180077","DOI":"10.1001\/jamaoncol.2018.0077","article-title":"Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel Cell Carcinoma","volume":"4","author":"D\u2019Angelo","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.oraloncology.2024.106971_b0035","first-page":"149","article-title":"Avelumab for advanced Merkel cell carcinoma: global real-world data on patient response and survival","volume":"14","author":"Lohray","year":"2023","journal-title":"Prag Obs Res"},{"issue":"26","key":"10.1016\/j.oraloncology.2024.106971_b0040","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.oraloncology.2024.106971_b0045","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1200\/JCO.18.01896","article-title":"Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma","volume":"37","author":"Nghiem","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10357","key":"10.1016\/j.oraloncology.2024.106971_b0050","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(22)01659-2","article-title":"Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomized, open label, phase 2 trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.oraloncology.2024.106971_b0055","first-page":"299","article-title":"A retrospective study of ipilimumab plus nivolumab in anti-PD-L1 \/PD-1 refractory Merkel cell carcinoma","volume":"45","author":"Shalhout","year":"2022","journal-title":"J immunother"},{"key":"10.1016\/j.oraloncology.2024.106971_b0060","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s11864-023-01118-8","article-title":"The evolving treatment landscape of Merkel cell carcinoma","volume":"24","author":"Singh","year":"2023","journal-title":"Curr Treat Op Oncol"},{"key":"10.1016\/j.oraloncology.2024.106971_b0065","unstructured":"FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma; 2023 22\/03\/2023. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-retifanlimab-dlwr-metastatic-or-recurrent-locally-advanced-merkel."},{"key":"10.1016\/j.oraloncology.2024.106971_b0070","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/bjd.21717","article-title":"Serum neuron-specific enolase independently predicts outcomes of patients with Merkel cell carcinoma","volume":"187","author":"Gambichler","year":"2022","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.oraloncology.2024.106971_b0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","article-title":"Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST)","volume":"35","author":"Gouda","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.oraloncology.2024.106971_b0080","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jdcr.2021.10.025","article-title":"Bespoke circulating tumor DNA as a biomarker for treatment response in a refractory Merkel cell carcinoma patient","volume":"18","author":"Yeakel","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"5","key":"10.1016\/j.oraloncology.2024.106971_b0085","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaad.2022.03.020","article-title":"Circulating tumor DNA as a predictive biomarker in Merkel cell carcinoma","volume":"87","author":"Park","year":"2022","journal-title":"JAAD"},{"key":"10.1016\/j.oraloncology.2024.106971_b0090","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.9566","article-title":"The relationship between circulating tumor DNA with Merkel cell carcinoma tumor burden and detection of recurrence","volume":"40","author":"Akaike","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oraloncology.2024.106971_b0095","unstructured":"https:\/\/www.rochefoundationmedicine.com\/f1cdxtech."},{"key":"10.1016\/j.oraloncology.2024.106971_b0100","unstructured":"https:\/\/info.foundationmedicine.com\/hubfs\/FMI%20Labels\/FoundationOne_Liquid_CDx_Label_Technical_Info.pdf."}],"container-title":["Oral Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368837524002896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368837524002896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T11:47:24Z","timestamp":1732189644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368837524002896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":20,"alternative-id":["S1368837524002896"],"URL":"https:\/\/doi.org\/10.1016\/j.oraloncology.2024.106971","relation":{},"ISSN":["1368-8375"],"issn-type":[{"value":"1368-8375","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Profound ctDNA and radiological responses after 2 cycles of avelumab in a metastatic Merkel cell carcinoma of the head and neck","name":"articletitle","label":"Article Title"},{"value":"Oral Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oraloncology.2024.106971","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106971"}}